广告
加载中

六味地黄茶卖出一个亿 三诺食疗能否将“补肾良方”变成“日常快乐水”?

付艳翠 2026-04-10 10:15
付艳翠 2026/04/10 10:15

邦小白快读

EN
全文速览

文章聚焦三诺食疗六味地黄茶的销售成就与挑战,提供实用干货信息。

1. 重点信息:六味地黄茶借势“六味地黄丸”的补肾认知上市,单瓶售价6元,五个月销售额破1亿元,但面临复购难题;药食同源市场规模达3700亿元,全产业链估值超2万亿元。

2. 实操干货:消费者反馈产品口味不佳(如琳琳和李涛体验),导致好奇购买后难以持续消费;建议关注产品改进口感和安全性,避免因猎奇心理流失用户;同质化竞争加剧,京东平台出现多个类似品牌,需提升差异化。

风险与机会:产品存在虚假宣传风险(如暗示补肾功能),监管记录显示三诺有生产环境问题;机会在于细分人群需求(如男性精力养护、女性驱寒),但需确保产品普适性。

品牌营销和产品研发的干货总结。

1. 品牌营销:三诺借势“六味地黄丸”传统认知,通过小红书等平台暗示补肾功能吸引流量;针对细分人群策略(男性六味地黄饮、女性紫苏姜汤),直击痛点如体寒和精力养护;消费趋势显示健康养生兴起,Z世代接受“朋克养生”。

2. 品牌渠道建设:产品在超市和便利店上架,但小卖部渗透不足;渠道依赖经销商,招商势头强劲,目标三年销售额达5亿元。

3. 品牌定价和价格竞争:单瓶定价6元,面临同质化竞争(如轻上、黔宗味等品牌跟进),价格战风险高。

4. 产品研发:基于古方(六味地黄丸)创新配方,添加红皮甘蔗等辅料,但口味改良不足;用户行为观察显示首购靠好奇,复购靠适口性,需优化研发。

5. 消费趋势和用户行为:药食同源产业爆发式增长,消费者偏好红豆薏米水等易接受产品;代表企业如同仁堂、片仔癀进入市场,强化品牌信任叙事。

市场机会与风险的综合分析。

1. 政策解读:产品面临虚假宣传红线(如暗示补肾功效),监管处罚风险高;需遵守不能宣称药品功效的法规。

2. 增长市场:药食同源市场规模突破3700亿元,潜力未开发(如106种食材产业化不足);消费需求变化显示健康意识增强,机会在细分人群(如35岁以上男性)。

3. 事件应对措施:针对复购难题(口味差),可学习三诺的营销策略(借势传统认知),但需改进产品;正面影响包括亿元销售额示范效应,负面影响是品控问题影响信任。

4. 风险提示:同质化竞争激烈(数十家品牌跟进),渠道渗透障碍(小卖部难进);机会提示在电商平台(如京东)拓展。

5. 可学习点和最新商业模式:借鉴药食同源模式(如借古方新造),合作方式包括与药企联名(如太极集团与天府可乐);扶持政策未提及,但需关注合规。

生产需求与商业机会的干货总结。

1. 产品生产和设计需求:三诺有生产环境问题(如车间漏水、清洁不达标),需加强品控和委托检验制度;设计基于古方(六味地黄丸),但配方调整(添加甘蔗等)需考虑普适性和口味改良。

2. 商业机会:养生水市场增长快(规模3700亿元),机会在红豆薏米水等受欢迎产品;代表企业如露露、盼盼食品进入,启示可开发高频消费品。

3. 推进数字化和电商启示:电商平台如京东有销售,显示数字化渠道潜力;需结合线上推广(如小红书宣传),提升产品可及性。

风险与案例:品控失误影响品牌(三诺监管记录),案例显示消费者偏好易接受口味;数据支持市场规模,启示工厂需优化生产流程。

行业趋势与解决方案的干货总结。

1. 行业发展趋势:药食同源产业爆发式增长,市场规模达3700亿元,全产业链估值超2万亿元;趋势向“硬核草本”升级,竞争加剧(同仁堂、片仔癀等药企进入)。

2. 客户痛点:消费者口味反馈差(如琳琳和李涛体验),导致低复购;合规风险(虚假宣传隐患);渠道渗透难(小卖部缺货)。

3. 解决方案:针对痛点改进产品口感,确保适口性;提供合规咨询,避免宣传越界;帮助拓展渠道(如连锁超市),案例显示超市养生风潮正在兴起。

新技术与数据:文章未提新技术,但数据支持产业潜力;观点指出Z世代接受养生,但需解决日常化问题。

平台需求与运营管理的干货总结。

1. 商业对平台的需求和问题:消费者需好喝和广泛渠道的产品,但养生水在超市和便利店上架而小卖部少见;问题包括口味差影响复购,渠道渗透不足。

2. 平台的最新做法:招商势头强劲(三诺目标5亿元),超市货架摆放养生水;但需优化运营,如管理品控(三诺生产问题)。

3. 平台招商:吸引品牌(如糖酒会洽谈),但经销商反馈产业时机未到;合作方式可借鉴药企联名模式。

4. 运营管理和风险规避:管理上需确保产品安全(如空气洁净度监测),规避虚假宣传风向;数据支持市场规模3700亿元,机会在健康趋势。

案例与观点:经销商王伟认为“药味”饮料难高频消费,启示平台需筛选易接受产品。

产业动向与商业模式的干货总结。

1. 产业新动向:药食同源市场规模突破3700亿元,同质化竞争加剧(数十家品牌跟进);新动向包括药企(同仁堂、片仔癀)迁移信任到即饮产品。

2. 新问题:药食边界模糊(如不能宣称功效),引发监管挑战;品控问题(三诺生产环境缺陷)影响公信力;消费习惯难沉淀,需研究高频化路径。

3. 政策法规建议和启示:建议明确宣传规范,避免越界;监管启示来自三诺案例,需加强生产监督制度。

4. 商业模式:药食同源模式(借古方新造)能否可持续(如六味地黄茶1亿销售额昙花一现风险);代表企业案例显示品牌厚度不足(三诺 vs 同仁堂)。

数据与观点:市场规模数据;观点指出产业爆发需时间检验,商业模式依赖产品力。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

The article examines the sales achievements and challenges of Sannuo's Six-Ingredient Rehmannia Tea, offering practical insights.

1. Key Information: The tea leveraged existing consumer awareness of "Liuwei Dihuang Wan" (a traditional kidney-tonifying remedy) for its launch, priced at 6 RMB per bottle. It achieved over 100 million RMB in sales within five months but faces low repurchase rates. The broader "medicine-food homology" market is valued at 370 billion RMB, with the full industry chain exceeding 2 trillion RMB.

2. Practical Insights: Consumer feedback indicates poor taste (as experienced by users like Linlin and Litao), making it difficult to retain customers after initial curiosity-driven purchases. The article suggests improving flavor and safety to prevent user churn. Intensifying homogenized competition, with similar brands emerging on JD.com, necessitates greater product differentiation.

Risks & Opportunities: The product faces risks of false advertising (e.g., implying kidney-tonifying effects), and regulatory records show Sannuo has had production environment issues. Opportunities lie in serving niche demographics (e.g., energy maintenance for men, cold relief for women), but product universality must be ensured.

A summary of insights for brand marketing and product development.

1. Brand Marketing: Sannuo capitalized on traditional recognition of "Liuwei Dihuang Wan," using platforms like Xiaohongshu to subtly imply health benefits and attract traffic. Its strategy targets specific demographics (e.g., the Six-Ingredient drink for men, Perilla Ginger Soup for women), addressing pain points like low energy and feeling cold. Consumer trends show rising health consciousness, with Gen Z embracing "punk wellness."

2. Channel Strategy: The product is available in supermarkets and convenience stores but has limited penetration in smaller grocery stores. Distribution relies on dealers, with strong recruitment momentum and a target of 5 billion RMB in sales within three years.

3. Pricing & Competition: Priced at 6 RMB per bottle, it faces intense homogenized competition (e.g., brands like Qingshang, Qianzongwei), creating high risk of price wars.

4. Product R&D: The formula innovates on a classic prescription but added ingredients like red-skinned sugarcane have not sufficiently improved taste. User behavior shows initial purchases are driven by curiosity, while repurchases depend on palatability, highlighting the need for R&D optimization.

5. Consumer Trends: The medicine-food homology industry is experiencing explosive growth. Consumers prefer easily acceptable products like red bean and barley water. Established players like Tongrentang and Pien Tze Huang are entering the market, strengthening narratives of brand trust.

A comprehensive analysis of market opportunities and risks.

1. Policy Interpretation: The product risks crossing the red line of false advertising (e.g., implying medicinal effects), facing high regulatory penalty risks. Sellers must comply with regulations prohibiting health claims for non-drug items.

2. Growth Market: The medicine-food homology market exceeds 370 billion RMB, with untapped potential (e.g., under-industrialization of 106 approved ingredients). Shifting consumer demand shows heightened health awareness, creating opportunities in niches like men over 35.

3. Strategic Response: To address low repurchase rates (due to poor taste), learn from Sannuo's marketing (leveraging traditional认知) but improve the product. Positive impacts include the demonstration effect of 100 million RMB sales; negatives involve quality control issues damaging trust.

4. Risk Alert: Fierce homogenized competition (dozens of similar brands) and channel penetration barriers (difficult access to small stores) are key risks. Opportunities exist in expanding on e-commerce platforms like JD.com.

5. Learnings & Business Models: Learn from the medicine-food homology model (revamping ancient formulas). Collaboration methods include co-branding with pharmaceutical companies (e.g., Taiji Group & Tianfu Cola). While specific support policies aren't mentioned, compliance is crucial.

A summary of production needs and commercial opportunities.

1. Production & Design Needs: Sannuo has had production environment issues (e.g., workshop leaks, inadequate cleaning), necessitating stronger quality control and third-party inspection systems. The design is based on a classic formula but recipe adjustments (adding sugarcane) require consideration for universal appeal and taste improvement.

2. Commercial Opportunities: The wellness beverage market is growing rapidly (370 billion RMB scale), with opportunities in popular products like red bean and barley water. Leading companies like Lulu and Panpan Foods entering the market indicate potential for developing high-frequency consumer goods.

3. Digital & E-commerce Insights: Sales on platforms like JD.com highlight the potential of digital channels. Factories should combine online promotion (e.g., Xiaohongshu marketing) to improve product accessibility.

Risks & Cases: Quality control failures damage brands (Sannuo's regulatory record). Case studies show consumer preference for easily acceptable flavors. Market size data suggests factories need to optimize production processes.

A summary of industry trends and solutions.

1. Industry Trends: The medicine-food homology industry is experiencing explosive growth, with a market size of 370 billion RMB and a full industry chain valuation exceeding 2 trillion RMB. The trend is upgrading towards "hardcore herbal" products, with intensifying competition as traditional pharma companies (Tongrentang, Pien Tze Huang) enter.

2. Client Pain Points: Poor consumer taste feedback (e.g., experiences of Linlin, Litao) leads to low repurchase rates. Compliance risks (false advertising hazards) and difficult channel penetration (stockouts in small stores) are major challenges.

3. Solutions: Address pain points by improving product taste for better palatability. Offer compliance consulting to avoid regulatory overstep. Assist with channel expansion (e.g., into chain supermarkets), as case studies show a rising wellness trend in supermarkets.

Technology & Data: The article doesn't mention new technologies, but data supports the industry's potential. Insights indicate Gen Z accepts wellness concepts but products need to fit into daily routines.

A summary of platform demands and operational management insights.

1. Merchant & Platform Needs: Consumers demand tasty products with wide availability, but wellness drinks are often in supermarkets/convenience stores yet scarce in small groceries. Key problems include poor taste hindering repurchase and insufficient channel penetration.

2. Platform Practices: There is strong merchant recruitment momentum (Sannuo targets 5 billion RMB), with wellness drinks placed on supermarket shelves. However, operations need optimization, particularly managing quality control (referencing Sannuo's production issues).

3. Merchant Recruitment: Platforms attract brands (e.g., negotiations at the Sugar & Wine Fair), but dealer feedback suggests the industry timing might not be fully ripe. Collaboration models can learn from pharma company co-branding.

4. Operations & Risk Management: Management must ensure product safety (e.g., air cleanliness monitoring) and avoid false advertising pitfalls. Market size data (370 billion RMB) confirms opportunities aligned with health trends.

Case & Viewpoint: Dealer Wang Wei's opinion that "medicinal-taste" drinks are hard to consume frequently suggests platforms should prioritize easily acceptable products.

A summary of industry movements and business models.

1. Industry Movements: The medicine-food homology market has surpassed 370 billion RMB, with intensifying homogenized competition (dozens of brands). A key movement is traditional pharma companies (Tongrentang, Pien Tze Huang) transferring consumer trust to ready-to-drink products.

2. Emerging Issues: Blurred lines between food and medicine (inability to claim efficacy) create regulatory challenges. Quality control issues (Sannuo's production defects) harm credibility. Establishing sustained consumption habits is difficult, requiring research into high-frequency usage pathways.

3. Policy & Regulatory Implications: Recommendations include clarifying advertising guidelines to prevent overstep. Regulatory lessons from the Sannuo case highlight the need for strengthened production supervision systems.

4. Business Models: The sustainability of the medicine-food homology model (revamping ancient formulas) is questionable (e.g., risk of Six-Ingredient Rehmannia Tea's 100 million RMB sales being short-lived). Case studies of representative companies reveal insufficient brand depth (Sannuo vs. Tongrentang).

Data & Viewpoints: Market size data is provided. A key viewpoint is that the industry's explosive growth needs time for validation, and business models ultimately depend on product strength.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

“男生过了35岁就喝它(六味地黄饮),这可是个好东西。”

“如果你老公过了35岁就满头大汗,床单枕套都是湿的,就让他喝六味地黄饮。”

“药膳协会三诺集团出品,用传统古方古法炮制,用了8种花花草草熬制,喝起来没什么怪味儿,有一股草木香气和淡淡的回甘。具体有啥作用,懂得都懂。”

……

三诺食疗在小红书的宣传视频和各种招商视频中,不断暗示六味地黄饮产品的“补肾”功能。

凭借“六味地黄丸”在国民心中“补肾、治虚”的强认知,将其嫁接到饮料上,让消费者产生“喝饮料=养生”的心理暗示,也让这家2009年在河南焦作成立的企业出了圈。

资料显示,三诺食疗推出的六味地黄茶已成为亿元爆款,并撕开了中式养生水的流量缺口。

不过,从早期的红豆薏米水等食材型养生水,到如今升级为“硬核草本”与“经典名方”的竞争,三诺食疗能否将“补肾良方”变成“日常快乐水”,依旧是未知数。

01 流量密码深陷复购难题

在巨头环伺的市场中,通过发布葡萄糖补水液、NFC果汁果然好喝和超级好喝系列等多款产品后,三诺食疗似乎终于凭借对细分人群的洞察,在中式养生水赛道找到了自己的生存空间。

在女性市场,三诺食疗推出的“紫苏姜汤”主要配料有“紫苏+生姜”这对中医认证的驱寒CP,并加入当归、红糖补气血,直击女性体寒、痛经等痛点,打造专属的暖养解决方案。

在男性市场,推出“六味地黄饮”系列则借势“六味地黄丸”传统认知,持续强化产品的“补肾”功能联想,满足了男性群体对精力养护的潜在需求。

资料显示,三诺食疗位于河南焦作,中国营养学会单位会员,是集研发、生产、销售于一体的现代化食品饮料企业。

公开数据显示,2025年8月,三诺食疗推出“六味地黄茶”,单瓶售价6元,在上市约五个月后,销售额已突破1亿元。

琳琳最初接触三诺食疗,正是从它家那款“紫苏姜汤”开始的。

“光听名字,紫苏配生姜,一股驱寒暖胃、健康养生的气息便扑面而来,让人忍不住想尝试。”不过,真正喝下的那一瞬间,一股独特的风味直冲琳琳味蕾,“说不上来,反正不好喝,再也没试过了。”

这之后,对于中式养生水类的“特色饮品”,琳琳就多了一份敬畏之心。

无独有偶,“六味地黄饮”被宣传以古方六味地黄丸为基础古方新造,保留熟地黄、山茱萸、山药等核心成分,以红皮甘蔗、茯苓、当归为“三辅”,但李涛最终也被其口味“劝退”。

“它确实剔除了中药的苦涩感,还有焦糖的中药味,说实话并不是很难喝。”李涛向「创业最前线」感慨,但因为长得太像中药了,半天才喝完,他以后不会再购买。

显然,当消费者购买产品是因为对某一种“草本概念”的好奇时,虽然可以依靠猎奇和流量获得首波流量,但长期生存还是依赖好喝适口才能产生复购。不然,一旦消费者好奇心消退,或者出现了更新奇的概念,用户可能会迅速流失。

事实上,中药口感即便改良,仍可能存在受众天花板,难以像普通茶饮那样实现高频消费。毕竟Z世代可以接受“朋克养生”,但现在的消费者还没准备好天天喝“药水”。

“红豆薏米水卖得最好,年轻人会偏爱一些,草本的就相对差很多。”超市销售员向「创业最前线」坦言。

“我觉得现在都是大厂自嗨。”正如快消品经销商陈涛曾语气犀利地向「创业最前线」预测,强中药配方的健康饮品,想要真正普及到大众日常,最少还要再教育市场5年。

02 药与食的边界博弈

“未来三年,六味地黄茶的销量目标直指5亿元。”三诺食疗相关负责人曾向媒体描绘了这样一幅蓝图。在他看来,按照当前的招商势头,这一目标并非遥不可及。

然而,在这份乐观的业绩预测背后,还存在一场药品与食品的边界博弈。

长期以来,“六味地黄丸”都是作为具有滋阴补肾之功效的药品存在。如今,作为普通食品销售,六味地黄饮面临的挑战之一就是不能像药品那样宣称功效。一旦过度暗示“补肾”“治疗”,便面临虚假宣传的红线,可能招致监管处罚风险。

与此同时,传统的六味地黄丸由熟地黄、山茱萸、山药、泽泻、牡丹皮、茯苓六味药材组成,三诺食疗的产品配方虽然在经典六味的基础上有所调整,但作为添加了中药属性的产品,其普适性也引发了质疑。

“地黄丸对寒湿体质的人就是毒药,本身寒凉,做成饮料又是冷的,对胃寒的人并不友好。”在社交媒体上有人评价道,“只宣传功效,不管产品属性,这未免有些本末倒置。”

轻轻也向「创业最前线」表示,她看了三诺食疗六味地黄饮的配料表,含量第一的是水,第二和第三分别是高糖的黄冰糖和红糖,“不仅没说中药成分如何,含糖量也较高,不建议多喝。”

与此同时,在不少经销商看来,这种徘徊在“药”与“饮”之间的模糊地带,或许能凭新奇吸引一时眼球,却很难真正融入消费者的日常,这也给其进入更多渠道造成阻碍。

最近,快消品经销商王伟在糖酒会期间多次收到主动洽谈的养生水品牌,但他只是礼貌性地尝了一口便放下了。

“不管喝多少次,这种药食同源的养生水喝起来都有点中药的口感。”王伟向「创业最前线」坦言,尽管品牌方极力描绘市场蓝海,但他总觉得产业爆发的时机未到。

在他看来,消费者或许会为“朋克养生”的标签买单一次,但很难将一瓶带着“药味”的饮料,像可乐或茶饮一样,变成高频次、场景化的日常消费品。这场由概念驱动的风潮,最终能否沉淀为真正的消费习惯,仍需时间检验。

「创业最前线」走访也发现,相比大型超市、连锁便利店们饮料货架上刮起了一股“养生风潮”,各种中式养生水被摆放在货架上,街边小卖部等渠道则鲜见其踪影。

“我的渠道点多在夫妻老婆店、学校小卖部、社区超市,所以我不打算进这些中式养生水。”一位经销商曾向「创业最前线」直言,“饮料主打的就是好喝,这种不是大众消费品,我不会考虑,‘卖不动的’。”

显然,当“养生”的概念无法转化为普适的口味和广泛的渠道渗透力时,三诺食疗的5亿蓝图,或许只是悬在“药食同源”风口上的一场豪赌。

03 同质化隐忧

对于三诺食疗而言,真正的考验或许并不是如何卖出下一个1亿元,而是在还没彻底卖爆之前,如何应对一场汹涌而来的“同质化浪潮”。

在京东电商平台搜索六味地黄饮关键词,结果不仅有三诺食疗品牌,还有轻上、黔宗味食品等品牌的身影。据自媒体“咖门”报道,该产品上市后吸引了数十家饮品企业跟进布局。

毫不意外,它们同样打着“古方新造”“药食同源”的旗号,试图分食这块刚刚有希望被做大的蛋糕。

“现在做同类型的品牌越来越多,我家有,别人家也有,大家卷得厉害。”一位做快消品的业内人士在饮料快消品直播间表示。

竞争远不止如此。

近年来,现代人生活状态的改变以及健康意识的增强,确实正推动药食同源产业迎来爆发式增长。2025中国特种食品产业大会数据显示,我国药食同源市场规模已突破3700亿元,全产业链估值超过2万亿元。

同时,扎堆进入中式养生水行业的品牌普遍认为,当下中国市场106种药食同源食材,实际大量“隐形成分”尚未充足产业化开发,如果参考人参、枸杞等明星食材的产业化程度,药食同源的潜力远未见底。

在此背景下,从早期的红豆薏米水等食材型养生水,升级为“硬核草本”与“经典名方”的竞争,赛道拥挤度正急剧上升。

不光是露露、盼盼食品、良品铺子这样的零食、饮料品牌,还有越来越多药企开始把长期积累的品牌信任与配方研发叙事,迁移到更高频、更日常的即饮产品上。

比如同仁堂旗下同仁堂饮料,推出酸梅汤饮、金银甘菊饮、桂圆姜枣饮、玫瑰花露、紫苏薄荷、霜后桑叶、参灵甘草等产品。以岭药业推出了连花清菲无糖植物饮料,葵花药业推出了小葵花露,片仔癀则推出了茶活力草本饮料,太极集团与天府可乐联名推出藿香味小可乐等。

而它们均具有传统底蕴和古方传承。

相比于同仁堂、片仔癀等拥有百年信誉背书的“正规军”,三诺食疗在品牌厚度上显得先天不足。当产品配方趋同、宣传口径一致时,消费者往往会本能地倾向于那个听起来更“正宗”、更“安全”的名字。

“作为消费者,我确实会更‘迷信’同仁堂、片仔癀这样知名药企的产品。”90后消费者罗莹的观点,代表了大多数人的选择逻辑。

而三诺食疗的隐患不仅在于外部竞争,更在于内部的品控与合规。

回溯监管记录,2023年,河南省市场监督管理局在监督检查中发现三诺食品集团存在生产环境堪忧和管理机制缺位多项问题。

比如车间内CIP系统化学品标识不清,洗涤剂领用记录缺失,个别管路甚至出现漏水现象,清洁作业区的空气洁净度监测也不符合要求。在生产和产品检验方面,其未能提供对受托方实施监督的记录,对不能自检的项目未建立委托检验制度,且与有资质检验机构的委托合同已过期等。

在“药食同源”这一对安全性要求极高的细分领域,这些过往的“黑历史”无疑是品牌信任的致命伤。

而在这条融合了健康需求与消费口感的赛道,最终能否成为可持续的增长极,仍需产品力与公信力给出最终答案。否则,这1亿的销售额,可能最终只是昙花一现。

注:文/付艳翠,文章来源:创业最前线(公众号ID:chuangyezuiqianxian),本文为作者独立观点,不代表亿邦动力立场。

文章来源:创业最前线

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

+1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0